vs

Side-by-side financial comparison of IONIS PHARMACEUTICALS INC (IONS) and Slide Insurance Holdings, Inc. (SLDE). Click either name above to swap in a different company.

Slide Insurance Holdings, Inc. is the larger business by last-quarter revenue ($389.3M vs $203.3M, roughly 1.9× IONIS PHARMACEUTICALS INC). Slide Insurance Holdings, Inc. runs the higher net margin — 35.8% vs -112.8%, a 148.7% gap on every dollar of revenue. On growth, Slide Insurance Holdings, Inc. posted the faster year-over-year revenue change (38.2% vs -10.3%).

Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.

United Property & Casualty Insurance Company, Inc. is an American property and casualty insurance company with headquarters in Florida. It writes commercial, residential, homeowners’, and flood insurance policies in several coastal states.

IONS vs SLDE — Head-to-Head

Bigger by revenue
SLDE
SLDE
1.9× larger
SLDE
$389.3M
$203.3M
IONS
Growing faster (revenue YoY)
SLDE
SLDE
+48.5% gap
SLDE
38.2%
-10.3%
IONS
Higher net margin
SLDE
SLDE
148.7% more per $
SLDE
35.8%
-112.8%
IONS

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IONS
IONS
SLDE
SLDE
Revenue
$203.3M
$389.3M
Net Profit
$-229.4M
$139.5M
Gross Margin
96.1%
Operating Margin
-105.5%
Net Margin
-112.8%
35.8%
Revenue YoY
-10.3%
38.2%
Net Profit YoY
-119.8%
50.8%
EPS (diluted)
$-1.35
$1.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IONS
IONS
SLDE
SLDE
Q1 26
$389.3M
Q4 25
$203.3M
$347.0M
Q3 25
$156.7M
$265.7M
Q2 25
$452.0M
$261.6M
Q1 25
$131.6M
Q4 24
$226.6M
Q3 24
$133.8M
Q2 24
$225.3M
Net Profit
IONS
IONS
SLDE
SLDE
Q1 26
$139.5M
Q4 25
$-229.4M
$170.4M
Q3 25
$-128.6M
$111.0M
Q2 25
$123.6M
$70.1M
Q1 25
$-146.9M
Q4 24
$-104.3M
Q3 24
$-140.5M
Q2 24
$-66.3M
Gross Margin
IONS
IONS
SLDE
SLDE
Q1 26
Q4 25
96.1%
Q3 25
98.5%
Q2 25
99.1%
Q1 25
98.9%
Q4 24
98.3%
Q3 24
99.2%
Q2 24
98.2%
Operating Margin
IONS
IONS
SLDE
SLDE
Q1 26
Q4 25
-105.5%
Q3 25
-102.2%
55.3%
Q2 25
30.9%
36.8%
Q1 25
-111.6%
Q4 24
-48.9%
Q3 24
-111.1%
Q2 24
-29.3%
Net Margin
IONS
IONS
SLDE
SLDE
Q1 26
35.8%
Q4 25
-112.8%
49.1%
Q3 25
-82.1%
41.8%
Q2 25
27.3%
26.8%
Q1 25
-111.6%
Q4 24
-46.1%
Q3 24
-105.0%
Q2 24
-29.4%
EPS (diluted)
IONS
IONS
SLDE
SLDE
Q1 26
$1.02
Q4 25
$-1.35
$1.23
Q3 25
$-0.80
$0.79
Q2 25
$0.70
$0.56
Q1 25
$-0.93
Q4 24
$-0.66
Q3 24
$-0.95
Q2 24
$-0.45

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IONS
IONS
SLDE
SLDE
Cash + ST InvestmentsLiquidity on hand
$2.7B
$1.2B
Total DebtLower is stronger
$1.8B
Stockholders' EquityBook value
$489.1M
$1.1B
Total Assets
$3.5B
$2.9B
Debt / EquityLower = less leverage
3.71×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IONS
IONS
SLDE
SLDE
Q1 26
$1.2B
Q4 25
$2.7B
$1.2B
Q3 25
$2.2B
$861.6M
Q2 25
$2.3B
$936.2M
Q1 25
$2.1B
Q4 24
$2.3B
Q3 24
$2.5B
Q2 24
$2.1B
Total Debt
IONS
IONS
SLDE
SLDE
Q1 26
Q4 25
$1.8B
Q3 25
$35.0M
Q2 25
$36.3M
Q1 25
Q4 24
$1.3B
Q3 24
Q2 24
Stockholders' Equity
IONS
IONS
SLDE
SLDE
Q1 26
$1.1B
Q4 25
$489.1M
$1.1B
Q3 25
$618.0M
$964.2M
Q2 25
$631.7M
$868.1M
Q1 25
$475.7M
Q4 24
$588.4M
Q3 24
$662.5M
Q2 24
$263.7M
Total Assets
IONS
IONS
SLDE
SLDE
Q1 26
$2.9B
Q4 25
$3.5B
$2.9B
Q3 25
$3.0B
$2.7B
Q2 25
$3.0B
$2.8B
Q1 25
$2.8B
Q4 24
$3.0B
Q3 24
$3.1B
Q2 24
$2.7B
Debt / Equity
IONS
IONS
SLDE
SLDE
Q1 26
Q4 25
3.71×
Q3 25
0.04×
Q2 25
0.04×
Q1 25
Q4 24
2.13×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IONS
IONS
SLDE
SLDE
Operating Cash FlowLast quarter
$-137.7M
Free Cash FlowOCF − Capex
$-159.0M
FCF MarginFCF / Revenue
-78.2%
Capex IntensityCapex / Revenue
10.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-320.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IONS
IONS
SLDE
SLDE
Q1 26
Q4 25
$-137.7M
Q3 25
$-131.4M
$25.3M
Q2 25
$151.3M
$350.4M
Q1 25
$-150.8M
Q4 24
$-116.1M
Q3 24
$-115.0M
Q2 24
$-119.9M
Free Cash Flow
IONS
IONS
SLDE
SLDE
Q1 26
Q4 25
$-159.0M
Q3 25
$-136.7M
$24.5M
Q2 25
$139.0M
$348.9M
Q1 25
$-163.4M
Q4 24
$-141.6M
Q3 24
$-124.0M
Q2 24
$-126.1M
FCF Margin
IONS
IONS
SLDE
SLDE
Q1 26
Q4 25
-78.2%
Q3 25
-87.2%
9.2%
Q2 25
30.8%
133.4%
Q1 25
-124.1%
Q4 24
-62.5%
Q3 24
-92.7%
Q2 24
-56.0%
Capex Intensity
IONS
IONS
SLDE
SLDE
Q1 26
Q4 25
10.5%
Q3 25
3.4%
0.3%
Q2 25
2.7%
0.6%
Q1 25
9.6%
Q4 24
11.3%
Q3 24
6.8%
Q2 24
2.8%
Cash Conversion
IONS
IONS
SLDE
SLDE
Q1 26
Q4 25
Q3 25
0.23×
Q2 25
1.22×
5.00×
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IONS
IONS

Products$58.0M29%
Spinraza Royalties$54.0M27%
Collaborative Agreement Revenue$52.4M26%
Wainus Royalties$16.0M8%
Wainua Joint Development Revenue$9.6M5%
Other Commercial$7.6M4%
Other Royalties$5.7M3%

SLDE
SLDE

Segment breakdown not available.

Related Comparisons